[Hemodynamic effects of vecuronium in man].
The cardiovascular effects of vecuronium (Organon NC 45 or Norcuron) in man were determined through different protocols using continuous recording of heart rate, arterial blood pressure and parameters obtained by a Swan-Ganz catheter. In healthy anaesthetized patients (n = 23), the effects of a dose of 0.1 mg X kg-1 pancuronium (group A) were compared to those of two doses of vecuronium: 0.1 mg X kg-1 (group B) and 0.3 mg X kg-1 (group C). Pancuronium induced an increase in heart rate (+12%), arterial pressure (+16%) and cardiac index (+8%). No change occurred with vecuronium. In patients under mechanical ventilation in an intensive care unit, we compared the effects of pancuronium 0.1 mg X kg-1 (group D; n = 10), d-tubocurarine (group E; n = 11), vecuronium 0.1 mg X kg-1 (group F; n = 9) and 0.3 mg X kg-1 (group G; n = 10). Pancuronium induced an increase in heart rate (+12%), arterial pressure (+8%) and cardiac index (+9%). d-Tubocurarine induced an increase in heart rate (+6%), a decrease in arterial pressure (-24%) and cardiac index (-17%). No change was observed after vecuronium 0.1 mg X kg-1. After vecuronium 0.3 mg X kg-1, the changes were minimal: a slight decrease in arterial pressure (-5%), a very slight (+3%) and transient (3 min) increase in heart rate were observed. The doses were approximately equipotent in groups A, B and C, whereas the dose of 0.3 mg X kg-1 in group G is about 10 times the 90% effective dose of vecuronium. In geriatric patients with per- or postoperative circulatory deficiency (group H; n = 10, mean age 83 yr), no hemodynamic side effects were observed. Vecuronium seems to be a non-depolarizing neuromuscular blocking agent devoid of cardiovascular side-effects at the generally usual doses.
D000328:Adult; D000368:Aged; D000768:Anesthesia, General / Q000379:methods; D004305:Dose-Response Relationship, Drug; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects*; D010197:Pancuronium / Q000009:adverse effects / Q000031:analogs & derivatives*; D012121:Respiration, Artificial; D014403:Tubocurarine / Q000009:adverse effects; D014673:Vecuronium Bromide
D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D010197:Pancuronium; D014403:Tubocurarine
Effets hémodynamiques du vécuronium chez l'homme.